Literature DB >> 19758803

Crosstalk in Met receptor oncogenesis.

Andrea Z Lai1, Jasmine V Abella, Morag Park.   

Abstract

The Met receptor tyrosine kinase (RTK) regulates several distinct biological processes, including cell scatter, cell invasion, cell survival and epithelial remodeling. MET is genetically altered through several mechanisms in multiple human cancers; these events are causally related to cancer initiation and progression, identifying Met as a potential therapeutic target. Recent evidence highlights additional roles for Met in cancer through crosstalk with other receptors and cell surface proteins. In this review, we discuss recent progress in our understanding of mechanisms of interaction between Met, the epidermal growth factor receptor family and other cell surface protein families, and how these contribute to signal crosstalk, oncogenesis and drug resistance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19758803     DOI: 10.1016/j.tcb.2009.07.002

Source DB:  PubMed          Journal:  Trends Cell Biol        ISSN: 0962-8924            Impact factor:   20.808


  91 in total

Review 1.  Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression.

Authors:  Alessia Locatelli; Kristopher A Lofgren; Andrea R Daniel; Nancy E Castro; Carol A Lange
Journal:  Horm Cancer       Date:  2012-04       Impact factor: 3.869

2.  An overview of the c-MET signaling pathway.

Authors:  Shawna Leslie Organ; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

Review 3.  Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis.

Authors:  Okkyung Rho; Dae Joon Kim; Karou Kiguchi; John Digiovanni
Journal:  Mol Carcinog       Date:  2010-07-20       Impact factor: 4.784

4.  Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.

Authors:  Hartmut Koeppen; Wei Yu; Jiping Zha; Ajay Pandita; Elicia Penuel; Linda Rangell; Rajiv Raja; Sankar Mohan; Rajesh Patel; Rupal Desai; Ling Fu; An Do; Vaishali Parab; Xiaoling Xia; Tom Januario; Sharianne G Louie; Ellen Filvaroff; David S Shames; Ignacio Wistuba; Marina Lipkind; Jenny Huang; Mirella Lazarov; Vanitha Ramakrishnan; Lukas Amler; See-Chun Phan; Premal Patel; Amy Peterson; Robert L Yauch
Journal:  Clin Cancer Res       Date:  2014-03-31       Impact factor: 12.531

Review 5.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

6.  Fas ligand enhances malignant behavior of tumor cells through interaction with Met, hepatocyte growth factor receptor, in lipid rafts.

Authors:  Huan-Ching Lin; Po-Yin Lai; Yu-ping Lin; Jyun-Yuan Huang; Bei-Chang Yang
Journal:  J Biol Chem       Date:  2012-04-25       Impact factor: 5.157

Review 7.  Exploitation of the ubiquitin system by invading bacteria.

Authors:  Olivia Steele-Mortimer
Journal:  Traffic       Date:  2010-11-24       Impact factor: 6.215

8.  Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition.

Authors:  Ying Zhang; Kaitlyn E Farenholtz; Yanzhi Yang; Fadila Guessous; Charles G Dipierro; Valerie S Calvert; Jianghong Deng; David Schiff; Wenjun Xin; Jae K Lee; Benjamin Purow; James Christensen; Emanuel Petricoin; Roger Abounader
Journal:  Clin Cancer Res       Date:  2013-02-05       Impact factor: 12.531

9.  Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.

Authors:  Magda Bahcall; Mark M Awad; Lynette M Sholl; Frederick H Wilson; Man Xu; Stephen Wang; Sangeetha Palakurthi; Jihyun Choi; Elena V Ivanova; Giulia C Leonardi; Bryan C Ulrich; Cloud P Paweletz; Paul T Kirschmeier; Masayuki Watanabe; Hideo Baba; Mizuki Nishino; Rebecca J Nagy; Richard B Lanman; Marzia Capelletti; Emily S Chambers; Amanda J Redig; Paul A VanderLaan; Daniel B Costa; Yu Imamura; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2018-08-02       Impact factor: 12.531

10.  Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.

Authors:  Ken Suzawa; Michael Offin; Daniel Lu; Christopher Kurzatkowski; Morana Vojnic; Roger S Smith; Joshua K Sabari; Huichun Tai; Marissa Mattar; Inna Khodos; Elisa de Stanchina; Charles M Rudin; Mark G Kris; Maria E Arcila; William W Lockwood; Alexander Drilon; Marc Ladanyi; Romel Somwar
Journal:  Clin Cancer Res       Date:  2018-10-23       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.